Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraoperative low-dose esketamine for prevention of postoperative delirium after hip arthroplasty in frail older adults
ChiCTR2400092310Phase 4Not yet recruiting
- Sponsor
- Shiyan Taihe Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of esketamine in postoperative delirium (POD) (2 arms), sponsored by Shiyan Taihe Hospital. Primary endpoint: Postoperative delirium. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
postoperative delirium (POD)
Beyond the preview
Go deeper on ChiCTR2400092310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092310.